content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on December 23, 2024</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CADRENAL THERAPEUTICS, INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)
  &nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="vertical-align: bottom; width: 2%; text-align: center; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>88-0860746</B></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>822 A1A North, Suite 306</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ponte Vedra, Florida 32082</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices and Zip
  Code)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CADRENAL THERAPEUTICS,&nbsp;INC. 2022 SUCCSESOR
  EQUITY INCENTIVE PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CADRENAL THERAPEUTICS, INC. 2022 EQUITY INCENTIVE
  PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full title of the plans)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Quang Pham<BR>
  Chief Executive Officer<BR>
  Cadrenal Therapeutics,&nbsp;Inc.<BR>
  822 A1A North, Suite 306</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ponte Vedra, Florida 32082<BR>
  (904) 300-0701</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, and telephone number, including
  area code, of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Please send copies of all communications
  to:</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Leslie Marlow,&nbsp;Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Blank Rome LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1271 Avenue of the Americas</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10020</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(212) 885-5000</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
      <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated Filer &#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller Reporting Company &#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging Growth Company &#9746;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. &#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INTRODUCTION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cadrenal Therapeutics, Inc.
  (the &ldquo;Registrant&rdquo; or the &ldquo;Company&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
  its Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390023004535/ea172057-s8_cadrenal.htm">Form&nbsp;S-8</A> (Registration No. 333-269372)
  on January 24, 2023 (the &ldquo;2023 Registration Statement&rdquo;), pursuant to and in accordance with the requirements of Form S-8 for
  the purpose of registering under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), 3,010,000 (pre-reverse stock
  split) shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), issuable to employees,
  officers, directors, consultants and advisors of the Company under the Registrant&rsquo;s 2022 Successor Equity Incentive Plan (the &ldquo;2022
  Plan&rdquo;) and the Registrant&rsquo;s 2022 Equity Incentive Plan, as amended and restated (the &ldquo;Initial Plan&rdquo;). Pursuant
  to General Instruction E to Form S-8, the 2023 Registration Statement is incorporated into this Registration Statement by reference.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Registrant&rsquo;s also
  filed with the Commission its Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024021594/ea0201545-s8_cadrenal.htm">Form S-8</A> (Registration No. 333-277838)
  on March 12, 2024 (the &ldquo;2024 Registration Statement&rdquo;), pursuant to and in accordance with the requirements of General Instruction
  E to Form S-8, for the purpose of registering under the Securities Act an additional 694,550 shares (pre-reverse stock split) of Common
  Stock that may be issued pursuant to the 2022 Plan pursuant to an &ldquo;evergreen&rdquo; provision contained therein, which is equal
  to 20% of the total number of shares of Common Stock outstanding on December 31, 2023, resulting in a total of 2,604,550 shares (pre-reverse
  stock split) of Common Stock available for issuance under the 2022 Plan.&nbsp;Pursuant to General Instruction E to Form S-8, the 2024
  Registration Statement is incorporated into this Registration Statement by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 20, 2024, the
  Registrant effected a one-for-fifteen reverse stock split, which reduced the number of shares reserved under the 2022 Plan to 173,636.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to General Instruction
  E of Form S-8, the Registrant is filing this Registration Statement on Form S-8 (the &ldquo;Registration Statement&rdquo;) for the purpose
  of registering an additional 133,333 shares (post-reverse stock split) of the Common Stock that may be issued pursuant to the 2022 Plan
  , pursuant to an amendment to the 2022 Plan to increase the number of shares of Common Stock available for awards under the 2022 Plan
  by 133,333 (post-reverse stock split) shares of Common Stock to 306,969 (post-reverse stock split) shares of Common Stock, which amendment
  was approved by the Company&rsquo;s Board of Directors on May 25, 2024 and the Company&rsquo;s stockholders at its 2024 Annual Meeting
  of Stockholders held on July 29, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1. Plan Information*</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2. Registrant Information and Employee Plan Annual Information*</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">The information specified in Item 1 and Item 2 of Part I
  of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities
  Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the introductory note to Part I of Form S-8. The documents containing
  the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428. Such documents and the
  documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken
  together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
  REQUIRED IN THE REGISTRATION STATEMENT</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
  3. Incorporation of Documents by Reference</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Securities and Exchange Commission (the &ldquo;Commission&rdquo;) allows us to &ldquo;incorporate by reference&rdquo; the information
  we file with it which means that we can disclose important information to you by referring you to those documents instead of having to
  repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and
  later information that we file with the Commission will automatically update and supersede this information. We incorporate by reference
  the documents listed below and any future filings made with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities
  Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), between the date of this prospectus and the termination of the offering:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
      Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024021133/ea0201078-10k_cadrenal.htm">Form 10-K</A>
      for the year ended December 31, 2023 (Commission File No. 001-41596) filed with the Commission on March 11, 2024;</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
      Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024041014/ea0205058-10q_cadrenal.htm">Form 10-Q</A>
      for the quarter ended March 31, 2024 (Commission File No. 001-41596) filed with the Commission on May 9, 2024;</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
      Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024066107/ea0210248-10q_cadrenal.htm">Form 10-Q</A>
      for the quarter ended June 30, 2024 (Commission File No. 001-41596) filed with the Commission on August 7, 2024;</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
      Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024095393/ea0218928-10q_cadrenal.htm">Form 10-Q</A>
      for the quarter ended September 30, 2024 (Commission File No. 001-41596) filed with the Commission on November 7, 2024;</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&rsquo;s
      Current Reports on Form 8-K filed with the SEC <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024012649/ea193419-8k_cadrenal.htm">February 12, 2024</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1937993/000121390024020181/ea0201254-8k_cadrenal.htm">March 5, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/ea0201524-8k_cadrenal.htm">March 12, 2024</A>,
      <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024031371/ea0203558-8k_cadrenal.htm">April 9, 2024</A> (other than
      information furnished under Item 7.01 and exhibits related thereto), <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024040955/ea020556601-8k_cadrenal.htm">May
      9, 2024</A>, <FONT STYLE="background-color: white"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000101376224003209/ea0210326-8k_cadrenal.htm">July
      31, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024065400/ea0210607-8k_cadrenal.htm">August 6, 2024</A>
      (other than information furnished under Item 7.01 and exhibits related thereto), <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024069941/ea021156901-8k_cadrenal.htm">August
      16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024070883/ea021179601-8k_cadrenal.htm">August 20,
      2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024076144/ea021370601-8k_cadrenal.htm">September 5, 2024</A>,
      <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024081799/ea0215596-8k_cadrenal.htm">September 25, 2024</A> </FONT>(other
      than information furnished under Item 7.01 and exhibits related thereto), <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024090153/ea0218502-8k_cadrenal.htm">October
      24, 2024</A> (other than information furnished under Item 7.01 and exhibits related thereto) and <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024094155/ea0219768-8k_cadrenal.htm">November
      4, 2024</A><FONT STYLE="background-color: white">;</FONT></FONT></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024014316/ea193846-8ka1_cadrenal.htm">Form 8-K/A</A> filed with the SEC on February 15, 2024; and</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our
      common stock is set forth in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390023003079/ea171784-8a12b_cadrenalthera.htm">Form 8-A</A>&nbsp;filed with the SEC on January 17, 2023, as updated by the description of our common stock filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390023024260/f10k2022ex4-11_cadrenal.htm">Exhibit 4.11</A> to our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390023024260/f10k2022_cadrenalth.htm">Form 10-K</A> for the year ended December 31, 2022 filed with the SEC on March 30, 2023, including any amendments or reports filed for
      the purpose of updating such description.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
  other reports and documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other
  than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items)
  shall be deemed to be incorporated by reference in this Registration Statement and to be a part of this Registration Statement from the
  resp</FONT>ective date of filing of each of those reports or documents until the filing of a post-effective amendment to this Registration
  Statement which indicates either that all securities offered by this Registration Statement have been sold or which deregisters all of
  the securities under this Registration Statement then remaining unsold.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained in
  this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall
  be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration
  Statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration
  Statement modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or
  superseded, to constitute a part of this Registration Statement.&nbsp;<BR STYLE="clear: both">
  </P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 4. Description of Securities</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5. Interests of Named Experts and Counsel</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6. Indemnification of Directors and Officers</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted by Section&nbsp;102
  of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of incorporation that will
  be effective upon completion of this offering that eliminate the personal liability of our directors and officers for a breach of certain
  fiduciary duties as a director or officer, as applicable, except to the extent such an exemption from liability is not permitted under
  the Delaware General Corporation Law. An officer may not be exculpated for any action brought by or in the right of the corporation. A
  director may not be exculpated for improper distributions to stockholders. Further, pursuant to Delaware law a director or officer may
  not be exculpated for:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any breach of his or her duty of loyalty to us or our stockholders;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any act or omission not in good faith or that involves intentional
  misconduct or a knowing violation of law; and</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any transaction from which the director or officer derived
  an improper personal benefit.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These limitations of liability
  do not affect the availability of equitable remedies such as injunctive relief or rescission.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted by Section&nbsp;145
  of the Delaware General Corporation Law, our amended and restated bylaws that will be in effect upon completion of this offering provide
  that:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">we shall indemnify our directors and executive officers to
  the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions, and that we may indemnify other
  officers, employees or other agents;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">we shall advance expenses to our directors and executive officers
  in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;
  and</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the rights provided in our bylaws are not exclusive.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated bylaws
  provide that we will indemnify each person who was or is a party, or is or was threatened to be made a party, to any threatened, pending
  or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was,
  or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner,
  employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all
  such persons being referred to as an &ldquo;Indemnitee&rdquo;), or by reason of any action alleged to have been taken or omitted in such
  capacity, against all expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably
  incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a
  manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding,
  he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated bylaws provide that we will indemnify
  any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the
  fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our
  request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint
  venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses
  (including attorneys&rsquo; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in
  connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or
  she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to
  any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite
  such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding
  the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us
  against all expenses (including attorneys&rsquo; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced
  to an Indemnitee under certain circumstances.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above discussion of our
  amended and restated certificate of incorporation, amended and restated bylaws and the Delaware General Corporation Law is not intended
  to be exhaustive and is respectively qualified in its entirety by such amended and restated certificate of incorporation, amended and
  restated bylaws and the applicable Delaware General Corporation Law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted by the Delaware
  General Corporation Law, the registrant has entered into separate indemnification agreements with each of its current executive officers
  and intends to enter into separate indemnification agreements with each of the registrant&rsquo;s directors and certain of the registrant&rsquo;s
  officers which require the registrant, among other things, to indemnify them against certain liabilities which may arise by reason of
  their status as directors, officers or certain other employees.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant expects to
  obtain and maintain insurance policies under which its directors and officers are insured, within the limits and subject to the limitations
  of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result
  of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided
  by these policies may apply whether or not the registrant would have the power to indemnify such person against such liability under the
  provisions of the Delaware General Corporation Law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These indemnification provisions
  and the indemnification agreements that we have entered into, or intend to enter into, with the registrant&rsquo;s officers and directors
  may be sufficiently broad to permit indemnification of the registrant&rsquo;s officers and directors for liabilities (including reimbursement
  of expenses incurred) arising under the Securities Act.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In any underwriting agreement
  we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain
  conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act against certain liabilities.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7. Exemption from Registration Claimed</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 5%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 94%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex3-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant&rsquo;s Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022077850/fs12022a3ex3-2_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.2 to the registrant&rsquo;s Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024070883/ea021179601ex3-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant&rsquo;s Current Report on Form 8-K, filed on August 20, 2024, File No. 001-41596) </FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022580801ex5-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Blank Rome LLP</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022580801ex23-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of WithumSmith + Brown, PC, Independent Registered Public Accounting Firm</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022580801ex5-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Blank Rome LLP (contained in Exhibit 5.1)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#poa_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page hereto)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022058071/fs12022ex10-1_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadrenal Therapeutics, Inc. 2022 Equity Incentive Plan and form of Incentive Stock Option Agreement, Non-Qualified Stock Option Agreement for Officers and Other Employees, Non-Qualified Stock Option Agreement for Directors and Consultants, Restricted Stock Agreement, and Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.1 to the registrant&rsquo;s Registration Statement on Form S-1, filed on September 22, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-14_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadrenal Therapeutics, Inc. 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.14 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-15_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.15 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-16_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.16 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-17_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Stock Option Grant Notice and Stock Option Agreement and Notice of Exercise under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.17 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390022064170/fs12022a2ex10-18_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.18 to the registrant&rsquo;s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.7</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1937993/000121390024051803/ea0206592-04.htm#T9926"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference as Annex C to the Registrant&rsquo;s Definitive Proxy Statement on Schedule 14A, filed on June 11, 2024, File No. 001-41596)</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea022580801ex-fee_cadrenal.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table</FONT></A></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
  herewith.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>Item 9. Undertakings</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The undersigned Registrant hereby undertakes:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. To file, during any period in which offers
  or sales are being made, a post-effective amendment to this registration statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">i. To include any prospectus
  required by Section 10(a)(3) of the Securities Act of 1933, as amended;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ii. To reflect in the prospectus
  any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof)
  which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">iii. To include any material
  information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to
  such information in the registration statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information
  required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the Registrant pursuant
  to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. That, for the purpose of determining any liability
  under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the
  securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. To remove from registration by means of a post-effective
  amendment any of the securities being registered that remain unsold at the termination of the offering.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. That, for purposes of determining any
  liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to section 13(a) or section 15(d) of
  the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section
  15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a
  new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
  to be the initial bona fide offering thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. Insofar as indemnification for liabilities
  arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant, the Registrant
  has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act
  and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the
  Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any
  action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
  the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
  jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed
  by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">Pursuant to the requirements
  of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form&nbsp;S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
  authorized, in the City of Ponte Vedra, State of Florida, on this 23<SUP>rd</SUP> day of December, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CADRENAL THERAPEUTICS,&nbsp;INC.</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2"></TD></TR>
    <TR>
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; vertical-align: top; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Quang Pham</FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
      <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quang Pham</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
      <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="poa_001"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">Each person whose signature
  appears below constitutes and appoints Quang Pham and Matthew Szot his true and lawful attorney-in-fact and agent with full power of substitution
  and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
  amendments) to this Registration Statement on Form&nbsp;S-8 to be filed by Cadrenal Therapeutics,&nbsp;Inc., and to file the same, with
  all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
  and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could
  do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause
  to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">***</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.15pt">Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the
  dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 44%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Signature</B></P></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 37%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Title</B></P></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 17%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1.5pt solid"><B>Date</B></P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Quang Pham</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Quang Pham</P></TD>
      <TD>&nbsp;</TD>
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chairman of the Board and Chief Executive Officer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Matthew Szot</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Matthew Szot</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer<BR>
  (Principal Accounting and Financial Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ John R. Murphy</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John R. Murphy</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Steven Zelenkofske</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Zelenkofske</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Glynn Wilson</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glynn Wilson</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid">/s/ Robert Lisicki</P></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 23, 2024</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;Robert Lisicki</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">II-6</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0225808-s8_cadrenal.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 72039}]
metadata_filer: {"company-data": {"conformed-name": "Cadrenal Therapeutics, Inc.", "cik": "0001937993", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "880860746", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-284024", "film-number": "241574453"}, "business-address": {"street1": "822 A1A NORTH", "street2": "SUITE 300", "city": "PONTE VEDRA", "state": "FL", "zip": "32082", "phone": "904-300-0701"}, "mail-address": {"street1": "822 A1A NORTH", "street2": "SUITE 300", "city": "PONTE VEDRA", "state": "FL", "zip": "32082"}}
text: As filed with the Securities and Exchange Commission
  on December 23, 2024
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933
  CADRENAL THERAPEUTICS, INC.
  (Exact name of registrant as specified in its charter)
  Delaware
  88-0860746
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification No.)
  822 A1A North, Suite 306
  Ponte Vedra, Florida 32082
  (Address of Principal Executive Offices and Zip
  Code)
  CADRENAL THERAPEUTICS, INC. 2022 SUCCSESOR
  EQUITY INCENTIVE PLAN
  CADRENAL THERAPEUTICS, INC. 2022 EQUITY INCENTIVE
  PLAN
  (Full title of the plans)
  Quang Pham
  Chief Executive Officer
  Cadrenal Therapeutics, Inc.
  822 A1A North, Suite 306
  Ponte Vedra, Florida 32082
  (904) 300-0701
  (Name, address, and telephone number, including
  area code, of agent for service)
  Please send copies of all communications
  to:
  Leslie Marlow, Esq.
  Blank Rome LLP
  1271 Avenue of the Americas
  New York, New York 10020
  (212) 885-5000
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer ☐
  Accelerated Filer ☐
  Non-accelerated filer ☒
  Smaller Reporting Company ☒
  Emerging Growth Company ☒
  If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
  INTRODUCTION
  Cadrenal Therapeutics, Inc.
  (the "Registrant" or the "Company") filed with the Securities and Exchange Commission (the "Commission")
  its Registration Statement on
  Form S-8
  (Registration No. 333-269372)
  on January 24, 2023 (the "2023 Registration Statement"), pursuant to and in accordance with the requirements of Form S-8 for
  the purpose of registering under the Securities Act of 1933, as amended (the "Securities Act"), 3,010,000 (pre-reverse stock
  split) shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), issuable to employees,
  officers, directors, consultants and advisors of the Company under the Registrant's 2022 Successor Equity Incentive Plan (the "2022
  Plan") and the Registrant's 2022 Equity Incentive Plan, as amended and restated (the "Initial Plan"). Pursuant
  to General Instruction E to Form S-8, the 2023 Registration Statement is incorporated into this Registration Statement by reference.
  The Registrant's also
  filed with the Commission its Registration Statement on
  Form S-8
  (Registration No. 333-277838)
  on March 12, 2024 (the "2024 Registration Statement"), pursuant to and in accordance with the requirements of General Instruction
  E to Form S-8, for the purpose of registering under the Securities Act an additional 694,550 shares (pre-reverse stock split) of Common
  Stock that may be issued pursuant to the 2022 Plan pursuant to an "evergreen" provision contained therein, which is equal
  to 20% of the total number of shares of Common Stock outstanding on December 31, 2023, resulting in a total of 2,604,550 shares (pre-reverse
  stock split) of Common Stock available for issuance under the 2022 Plan. Pursuant to General Instruction E to Form S-8, the 2024
  Registration Statement is incorporated into this Registration Statement by reference.
  On August 20, 2024, the
  Registrant effected a one-for-fifteen reverse stock split, which reduced the number of shares reserved under the 2022 Plan to 173,636.
  Pursuant to General Instruction
  E of Form S-8, the Registrant is filing this Registration Statement on Form S-8 (the "Registration Statement") for the purpose
  of registering an additional 133,333 shares (post-reverse stock split) of the Common Stock that may be issued pursuant to the 2022 Plan
  , pursuant to an amendment to the 2022 Plan to increase the number of shares of Common Stock available for awards under the 2022 Plan
  by 133,333 (post-reverse stock split) shares of Common Stock to 306,969 (post-reverse stock split) shares of Common Stock, which amendment
  was approved by the Company's Board of Directors on May 25, 2024 and the Company's stockholders at its 2024 Annual Meeting
  of Stockholders held on July 29, 2024.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  Item 1. Plan Information*
  Item 2. Registrant Information and Employee Plan Annual Information*
  *
  The information specified in Item 1 and Item 2 of Part I
  of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities
  Act of 1933, as amended (the "Securities Act"), and the introductory note to Part I of Form S-8. The documents containing
  the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428. Such documents and the
  documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken
  together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
  1
  PART II
  INFORMATION
  REQUIRED IN THE REGISTRATION STATEMENT
  Item
  3. Incorporation of Documents by Reference
  The
  Securities and Exchange Commission (the "Commission") allows us to "incorporate by reference" the information
  we file with it which means that we can disclose important information to you by referring you to those documents instead of having to
  repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and
  later information that we file with the Commission will automatically update and supersede this information. We incorporate by reference
  the documents listed below and any future filings made with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities
  Exchange Act of 1934, as amended (the "Exchange Act"), between the date of this prospectus and the termination of the offering:
  ●
  The Registrant's
      Annual Report on
  Form 10-K
  for the year ended December 31, 2023 (Commission File No. 001-41596) filed with the Commission on March 11, 2024;
  ●
  The Registrant's
      Quarterly Report on
  Form 10-Q
  for the quarter ended March 31, 2024 (Commission File No. 001-41596) filed with the Commission on May 9, 2024;
  ●
  The Registrant's
      Quarterly Report on
  Form 10-Q
  for the quarter ended June 30, 2024 (Commission File No. 001-41596) filed with the Commission on August 7, 2024;
  ●
  The Registrant's
      Quarterly Report on
  Form 10-Q
  for the quarter ended September 30, 2024 (Commission File No. 001-41596) filed with the Commission on November 7, 2024;
  ●
  The Registrant's
      Current Reports on Form 8-K filed with the SEC
  February 12, 2024
  ,
  March 5, 2024
  ,
  March 12, 2024
  ,
  April 9, 2024
  (other than
      information furnished under Item 7.01 and exhibits related thereto),
  May
      9, 2024
  ,
  July
      31, 2024
  ,
  August 6, 2024
  (other than information furnished under Item 7.01 and exhibits related thereto),
  August
      16, 2024
  ,
  August 20,
      2024
  ,
  September 5, 2024
  ,
  September 25, 2024
  (other
      than information furnished under Item 7.01 and exhibits related thereto),
  October
      24, 2024
  (other than information furnished under Item 7.01 and exhibits related thereto) and
  November
      4, 2024
  ;
  ●
  Our Current Report on
  Form 8-K/A
  filed with the SEC on February 15, 2024; and
  ●
  The description of our
      common stock is set forth in our registration statement on
  Form 8-A
  filed with the SEC on January 17, 2023, as updated by the description of our common stock filed as
  Exhibit 4.11
  to our Annual Report on
  Form 10-K
  for the year ended December 31, 2022 filed with the SEC on March 30, 2023, including any amendments or reports filed for
      the purpose of updating such description.
  All
  other reports and documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other
  than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items)
  shall be deemed to be incorporated by reference in this Registration Statement and to be a part of this Registration Statement from the
  resp
  ective date of filing of each of those reports or documents until the filing of a post-effective amendment to this Registration
  Statement which indicates either that all securities offered by this Registration Statement have been sold or which deregisters all of
  the securities under this Registration Statement then remaining unsold.
  Any statement contained in
  this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall
  be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration
  Statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration
  Statement modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or
  superseded, to constitute a part of this Registration Statement.
  II-
  1
  Item 4. Description of Securities
  Not applicable.
  Item 5. Interests of Named Experts and Counsel
  Not applicable.
  Item 6. Indemnification of Directors and Officers
  As permitted by Section 102
  of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of incorporation that will
  be effective upon completion of this offering that eliminate the personal liability of our directors and officers for a breach of certain
  fiduciary duties as a director or officer, as applicable, except to the extent such an exemption from liability is not permitted under
  the Delaware General Corporation Law. An officer may not be exculpated for any action brought by or in the right of the corporation. A
  director may not be exculpated for improper distributions to stockholders. Further, pursuant to Delaware law a director or officer may
  not be exculpated for:
  ●
  any breach of his or her duty of loyalty to us or our stockholders;
  ●
  any act or omission not in good faith or that involves intentional
  misconduct or a knowing violation of law; and
  ●
  any transaction from which the director or officer derived
  an improper personal benefit.
  These limitations of liability
  do not affect the availability of equitable remedies such as injunctive relief or rescission.
  As permitted by Section 145
  of the Delaware General Corporation Law, our amended and restated bylaws that will be in effect upon completion of this offering provide
  that:
  ●
  we shall indemnify our directors and executive officers to
  the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions, and that we may indemnify other
  officers, employees or other agents;
  ●
  we shall advance expenses to our directors and executive officers
  in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;
  and
  ●
  the rights provided in our bylaws are not exclusive.
  Our amended and restated bylaws
  provide that we will indemnify each person who was or is a party, or is or was threatened to be made a party, to any threatened, pending
  or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was,
  or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner,
  employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all
  such persons being referred to as an "Indemnitee"), or by reason of any action alleged to have been taken or omitted in such
  capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably
  incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a
  manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding,
  he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated bylaws provide that we will indemnify
  any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the
  fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our
  request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint
  venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses
  (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in
  connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or
  she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to
  any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite
  such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding
  the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us
  against all expenses (including attorneys' fees) actually and reasonably incurred in connection therewith. Expenses must be advanced
  to an Indemnitee under certain circumstances.
  II-
  2
  The above discussion of our
  amended and restated certificate of incorporation, amended and restated bylaws and the Delaware General Corporation Law is not intended
  to be exhaustive and is respectively qualified in its entirety by such amended and restated certificate of incorporation, amended and
  restated bylaws and the applicable Delaware General Corporation Law.
  As permitted by the Delaware
  General Corporation Law, the registrant has entered into separate indemnification agreements with each of its current executive officers
  and intends to enter into separate indemnification agreements with each of the registrant's directors and certain of the registrant's
  officers which require the registrant, among other things, to indemnify them against certain liabilities which may arise by reason of
  their status as directors, officers or certain other employees.
  The registrant expects to
  obtain and maintain insurance policies under which its directors and officers are insured, within the limits and subject to the limitations
  of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result
  of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided
  by these policies may apply whether or not the registrant would have the power to indemnify such person against such liability under the
  provisions of the Delaware General Corporation Law.
  These indemnification provisions
  and the indemnification agreements that we have entered into, or intend to enter into, with the registrant's officers and directors
  may be sufficiently broad to permit indemnification of the registrant's officers and directors for liabilities (including reimbursement
  of expenses incurred) arising under the Securities Act.
  In any underwriting agreement
  we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain
  conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act against certain liabilities.
  Item 7. Exemption from Registration Claimed
  Not applicable.
  II-
  3
  PART II
  INFORMATION REQUIRED IN REGISTRATION STATEMENT
  Item 8. Exhibits.
  Exhibit
  Description
  4.1
  Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant's Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)
  4.2
  Amended and Restated Bylaws of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.2 to the registrant's Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)
  4.3
  Certificate of Amendment of Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K, filed on August 20, 2024, File No. 001-41596)
  5.1*
  Opinion of Blank Rome LLP
  23.1*
  Consent of WithumSmith + Brown, PC, Independent Registered Public Accounting Firm
  23.2*
  Consent of Blank Rome LLP (contained in Exhibit 5.1)
  24.1*
  Power of Attorney (included on signature page hereto)
  99.1
  Cadrenal Therapeutics, Inc. 2022 Equity Incentive Plan and form of Incentive Stock Option Agreement, Non-Qualified Stock Option Agreement for Officers and Other Employees, Non-Qualified Stock Option Agreement for Directors and Consultants, Restricted Stock Agreement, and Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.1 to the registrant's Registration Statement on Form S-1, filed on September 22, 2022, File No. 333-267562)
  99.2
  Cadrenal Therapeutics, Inc. 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.14 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.3
  Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.15 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.4
  Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.16 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.5
  Form of Stock Option Grant Notice and Stock Option Agreement and Notice of Exercise under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.17 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.6
  Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.18 to the registrant's Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
  99.7
  Amendment to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference as Annex C to the Registrant's Definitive Proxy Statement on Schedule 14A, filed on June 11, 2024, File No. 001-41596)
  107*
  Filing Fee Table
  *
  Filed
  herewith.
  II-
  4
  Item 9. Undertakings
  The undersigned Registrant hereby undertakes:
  1. To file, during any period in which offers
  or sales are being made, a post-effective amendment to this registration statement:
  i. To include any prospectus
  required by Section 10(a)(3) of the Securities Act of 1933, as amended;
  ii. To reflect in the prospectus
  any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof)
  which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement;
  iii. To include any material
  information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to
  such information in the registration statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information
  required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the Registrant pursuant
  to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement.
  2. That, for the purpose of determining any liability
  under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the
  securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  3. To remove from registration by means of a post-effective
  amendment any of the securities being registered that remain unsold at the termination of the offering.
  4. That, for purposes of determining any
  liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to section 13(a) or section 15(d) of
  the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section
  15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a
  new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
  to be the initial bona fide offering thereof.
  5. Insofar as indemnification for liabilities
  arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant, the Registrant
  has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act
  and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the
  Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any
  action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
  the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
  jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed
  by the final adjudication of such issue.
  II-
  5
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
  authorized, in the City of Ponte Vedra, State of Florida, on this 23
  rd
  day of December, 2024.
  CADRENAL THERAPEUTICS, INC.
  By:
  /s/ Quang Pham
  Name:
  Quang Pham
  Title:
  Chairman of the Board and Chief Executive Officer
  POWER OF ATTORNEY
  Each person whose signature
  appears below constitutes and appoints Quang Pham and Matthew Szot his true and lawful attorney-in-fact and agent with full power of substitution
  and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
  amendments) to this Registration Statement on Form S-8 to be filed by Cadrenal Therapeutics, Inc., and to file the same, with
  all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
  and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could
  do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause
  to be done by virtue hereof.
  ***
  Pursuant to the requirements
  of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the
  dates indicated.
  Signature
  Title
  Date
  /s/ Quang Pham
  Quang Pham
  Chairman of the Board and Chief Executive Officer
  (Principal Executive Officer)
  December 23, 2024
  /s/ Matthew Szot
  Matthew Szot
  Chief Financial Officer
  (Principal Accounting and Financial Officer)
  December 23, 2024
  /s/ John R. Murphy
  John R. Murphy
  Director
  December 23, 2024
  /s/ Steven Zelenkofske
  Steven Zelenkofske
  Director
  December 23, 2024
  /s/ Glynn Wilson
  Glynn Wilson
  Director
  December 23, 2024
  /s/ Robert Lisicki
  Director
  December 23, 2024
  Robert Lisicki
  II-6